We would welcome your comments on the draft new monograph to be incorporated into the AWMSG-endorsed “Primary care antimicrobial guidelines”.
Since November 2021, COVID-19 antiviral treatments nirmatrelvir plus ritonavir (Paxlovid®) and molnupiravir (Lagevrio®) were only available through health board operated treatment pathways with the medicines supplied from centrally procured stock.
As stated in the Welsh Health Circular "Changes to prescribing antiviral and antibody treatments for COVID-19 (WHC/2025/010)", antiviral treatments for COVID-19 will be routinely available from late Spring 2025, with eligible patients being able to contact their GP practice or out-of-hours service if they test positive for COVID-19, to be clinically assessed for prescription of anti-viral medication. Prescriptions will be able to be dispensed by community pharmacies and dispensing doctors.
The monograph presented in this document is proposed to be included as part of the AWMSG-endorsed “Primary care antimicrobial guidelines” (published March 2022; last updated April 2025), and provides guidance on the use of antiviral and monoclonal antibody treatments in adults who are at increased risk of progression to severe COVID-19.
The document and associated feedback form can be accessed below.
Closing date: 18th June 2025
⇩ Primary care antimicrobial guidelines - Monograph for the treatment of COVID-19 - Consultation draft 95KB (PDF) |
⇩ Primary care antimicrobial guidelines - Monograph for the treatment of COVID-19 - Consultation feedback form 37KB (Word document) |